These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 36840914)

  • 1. Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing.
    Shao T; Zhao M; Liang L; Tang W
    BioDrugs; 2023 May; 37(3):421-432. PubMed ID: 36840914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Front Public Health; 2023; 11():1156427. PubMed ID: 37727602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing.
    Gan Y; Shi F; Zhu H; Han S; Li D
    Front Pharmacol; 2023; 14():1241130. PubMed ID: 37547339
    [No Abstract]   [Full Text] [Related]  

  • 4. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis.
    Zhu Y; Liu K; Qin Q; Zhu H
    Front Immunol; 2022; 13():1044678. PubMed ID: 36685541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China.
    Xiang G; Jiang T; Gan L; Wu Y; Zhang N; Xing H; Su H; Li Y; Peng D; Ni R; Liu Y
    Front Immunol; 2023; 14():1223020. PubMed ID: 37720211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
    Liu S; Jiang N; Dou L; Li S
    Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial.
    Xiang H; Meng K; Wu M; Tan C
    Expert Rev Pharmacoecon Outcomes Res; 2024 Oct; 24(8):1043-1051. PubMed ID: 38984534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis.
    Liang X; Meng M; Qin S; Chen X; Li Y
    Sci Rep; 2024 Jun; 14(1):14496. PubMed ID: 38914660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of serplulimab plus chemotherapy as the first-line treatment of oesophageal squamous cell carcinoma in China.
    Chen F; Long Y; Yang J; Zhong K; Liu B
    BMJ Open; 2023 Dec; 13(12):e078924. PubMed ID: 38149425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sotorasib versus Docetaxel for treatment of US and Chinese patients with advanced non-small-cell lung cancer with KRAS p.G12C-mutated: A cost-effectiveness analysis to inform drug pricing.
    Jiang Y; Zhao M; Liu R; Zheng X
    Medicine (Baltimore); 2023 Dec; 102(50):e36387. PubMed ID: 38115313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
    Lin YT; Zhou CC; Xu K; Zhang MD; Li X
    Ther Adv Med Oncol; 2023; 15():17588359231213621. PubMed ID: 38028139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China.
    Long Y; Xu Y; Liao L; Zhou Y; Wang H
    BMJ Open; 2023 Aug; 13(8):e072106. PubMed ID: 37586861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis.
    Yi L; Zhou Z; Zeng X; Tan C; Liu Q
    Front Immunol; 2024; 15():1408928. PubMed ID: 39035009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China.
    Kang S; Liu H
    Expert Rev Pharmacoecon Outcomes Res; 2024 Nov; 24(9):1081-1088. PubMed ID: 37936507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients.
    Zheng H; Zeng Y; Wen F; Hu M
    Front Immunol; 2024; 15():1382088. PubMed ID: 38711525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma.
    Zhang L; Su H; Liang X; Chen X; Li Y
    Sci Rep; 2024 Jul; 14(1):17734. PubMed ID: 39085374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib plus pembrolizumab in the patients with advanced previously treated endometrial cancer: A cost-effectiveness analysis in the United States and in China.
    Liao X; Wu Y; Lin D; Gu D; Luo S; Huang X; Xu X; Weng X; Lin S
    J Obstet Gynaecol Res; 2024 May; 50(5):881-889. PubMed ID: 38485235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinoma.
    Zheng Z; Fang L; Cai H; Zhu H
    Immunotherapy; 2023 Sep; 15(13):1045-1055. PubMed ID: 37401267
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma.
    Zheng H; Li J; Wen F; Su N
    Front Oncol; 2023; 13():1216960. PubMed ID: 38023250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer.
    Zheng Z; Chen H; Cai H
    Front Oncol; 2023; 13():1259574. PubMed ID: 38282674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.